Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 29 references it cites were found in a registry or an index.

A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study

Open access
Guo, Qinghong, Li, Qiang, Wang, Jiong, Liu, Min, Wang, Yuping, Chen, Zhaofeng, Ye, Yuwei, Guan, Quanlin, Zhou, Yongning · 2019 · Medicine

Abstract

Aim: To evaluate the efficacy and safety of celecoxib combined with chemotherapy in the treatment of metastatic or postoperative recurrent gastric cancer. Methods: This preliminary, three-center, clinical trial study was conducted between September 2010 and December 2016. In the experimental group (n = 100), patients were treated with celecoxib combined with chemotherapy, and chemotherapy alone was used in the control group. Progression-free survival (PFS) was considered as the primary efficacy parameter. Overall survival (OS), remission rate (RR), quality of life (QOL) and drug safety were considered as the secondary efficacy parameters. Results: The PFS of the experimental group was 6 months, which was not significantly longer than that of the control group (5 months, P = .73). The average OS was not significantly different between the experimental group (12 months) and the control group (10 months, P = .59). The average OS of the COX-2 positive patients in the experimental group was 14 months and it was significantly longer than the 10-month OS in the control group (P = .01). The PFS of the COX-2 positive patients in the experimental group was 7.5 months, significantly longer than the 5-month PFS of patients in the control group (P < .001). No statistical significance was identified in the incidence of nausea, neutropenia, anorexia, peripheral neurotoxicity, diarrhea, vomiting, asthenia and thrombocytopenia. The EORTC QLQ-C30 questionnaire revealed that the overall QOL of the experimental group was significantly higher than that of the control group (P < .05). No statistical significance was found in the scores of functioning scale between the 2 groups. However, the scores of the symptom scale, especially for pain and fatigue in the experimental group was remarkably higher than that in the control group (P < .05). The overall score of EORTC QLQ-STO22 for the experimental group was considerably higher compared to that for the control group (P < .05). No statistical significance was identified in term of the domains of restrictions on feeding, dysphagia, anxiety, reflux, sense of taste, dry mouth, hair loss and body shape between the 2 groups (P > .05 for all mentioned outcomes). Conclusion: Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000016234

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of patients screening, grouping, and follow-up.
Figure 1 Flow chart of patients screening, grouping, and follow-up.CC BY-NC · PubMed Central
Figure 2 Immunohistochemical staining of COX-2 in gastric cancer tissues.
Figure 2 Immunohistochemical staining of COX-2 in gastric cancer tissues.CC BY-NC · PubMed Central
Figure 3 Comparison of OS (A) and PFS (B) in gastric cancer patients between the 2 groups.
Figure 3 Comparison of OS (A) and PFS (B) in gastric cancer patients between the 2 groups.CC BY-NC · PubMed Central
Figure 4 Comparison of OS (A) and PFS (B) in gastric cancer patients whit positive COX-2 between 2 groups.
Figure 4 Comparison of OS (A) and PFS (B) in gastric cancer patients whit positive COX-2 between 2 groups.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Tang, 2015, Advances in the treatment of gastric cancer with non-cytotoxic drugs, Chin J Pract Intern Med, 12, 1062

Cited by

See all 53

Metadata

Authors
Guo, Q., Li, Q., Wang, J., Liu, M., Wang, Y., Chen, Z., Ye, Y., Guan, Q., & Zhou, Y.
Affiliations
  • Department of Gastroenterology
  • First Hospital of Lanzhou University (CN)
Corresponding author
Zhou, Yongning
Venue
Medicine
Published
2019-07
Volume
98
Issue
27
Pages
e16234
ISSN
  • 0025-7974 (ISSN-L)
  • 1536-5964
OpenAlex
W2956263305
Cited by
53
References
29
Citations by year
2026: 2 · 2025: 8 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 12 · 2019: 1
FWCI
5.33
Type
journal article
Language
en
Open access
Locations
  • Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lanzhou University Institutional Repository (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
celecoxib, gastric cancer, metastatic gastric cancer, recurrent gastric cancer, COX-2 inhibition, combination chemotherapy, progression-free survival, overall survival, quality of life, drug safety, COX-2 expression, postoperative recurrence, EORTC QLQ-C30, neutropenia
MeSH terms
Celecoxib, Capecitabine, Oxaliplatin, Adolescent, Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Tegafur, Gastrectomy, Humans, Injections, Intravenous, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Retrospective Studies, Stomach Neoplasms, Treatment Outcome, Chemotherapy, Adjuvant, Disease-Free Survival, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. https://app.cochat.ai/papers/10.1097/md.0000000000016234
The paper
Guo, Q., Li, Q., Wang, J., Liu, M., Wang, Y., Chen, Z., Ye, Y., Guan, Q., & Zhou, Y. (2019). A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. Medicine. https://doi.org/10.1097/md.0000000000016234

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.